Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis

Purpose: Current morphology-based glioma classification methods do not adequately reflect the complex biology of gliomas, thus limiting their prognostic ability. In this study, we focused on anaplastic oligodendroglioma and glioblastoma, which typically follow distinct clinical courses. Our goal was to construct a clinically useful molecular diagnostic system based on gene expression profiling. Experimental Design: The expression of 3,456 genes in 32 patients, 12 and 20 of whom had prognostically distinct anaplastic oligodendroglioma and glioblastoma, respectively, was measured by PCR array. Next to unsupervised methods, we did supervised analysis using a weighted voting algorithm to construct a diagnostic system discriminating anaplastic oligodendroglioma from glioblastoma. The diagnostic accuracy of this system was evaluated by leave-one-out cross-validation. The clinical utility was tested on a microarray-based data set of 50 malignant gliomas from a previous study. Results: Unsupervised analysis showed divergent global gene expression patterns between the two tumor classes. A supervised binary classification model showed 100% (95% confidence interval, 89.4-100%) diagnostic accuracy by leave-one-out cross-validation using 168 diagnostic genes. Applied to a gene expression data set from a previous study, our model correlated better with outcome than histologic diagnosis, and also displayed 96.6% (28 of 29) consistency with the molecular classification scheme used for these histologically controversial gliomas in the original article. Furthermore, we observed that histologically diagnosed glioblastoma samples that shared anaplastic oligodendroglioma molecular characteristics tended to be associated with longer survival. Conclusions: Our molecular diagnostic system showed reproducible clinical utility and prognostic ability superior to traditional histopathologic diagnosis for malignant glioma.

[1]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[3]  A. Markoe,et al.  Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. , 1997, International journal of radiation oncology, biology, physics.

[4]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[5]  J. Tonn,et al.  ECM‐mediated glioma cell invasion , 1998, Microscopy research and technique.

[6]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[7]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[8]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[9]  K Matsubara,et al.  Gene expression in mouse cerebellum during its development. , 2000, Gene.

[10]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[11]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Wegner.  Expression of transcription factors during oligodendroglial development , 2001, Microscopy research and technique.

[13]  R. Kiss,et al.  Galectin‐1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma , 2001, Glia.

[14]  S. Ishii,et al.  Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data , 2003, Genome Biology.

[15]  Jacqueline Palmari,et al.  PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. , 2002, International journal of radiation oncology, biology, physics.

[16]  Shuichi Tsutsumi,et al.  Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p , 2002, Oncogene.

[17]  S. Weis,et al.  Expression of tenascin‐C in various human brain tumors and its relevance for survival in patients with astrocytoma , 2003, Cancer.

[18]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[19]  Kristen R. Ross,et al.  The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. , 2003, The American journal of pathology.

[20]  G. Fuller,et al.  IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. , 2003, Cancer research.

[22]  C. Gondi,et al.  Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis , 2003, Oncogene.

[23]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Y. Sawamura,et al.  Expression of the Oligodendroglial Lineage‐Associated Markers Olig1 and Olig2 in Different Types of Human Gliomas , 2003, Journal of neuropathology and experimental neurology.

[25]  Michael E. Berens,et al.  Glioma Cell Motility is Associated with Reduced Transcription of Proapoptotic and Proliferation Genes: A cDNA Microarray Analysis , 2001, Journal of Neuro-Oncology.

[26]  S. Ishii,et al.  Molecular Prediction of Response to 5-Fluorouracil and Interferon-α Combination Chemotherapy in Advanced Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[27]  J. Isola,et al.  Analysis of p53 Tumor Suppressor Gene in Families with Multiple Glioma Patients , 2001, Journal of Neuro-Oncology.

[28]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[29]  Hiroyuki Aburatani,et al.  Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with Chromosome 1p Loss , 2004, Brain pathology.

[30]  Shinzaburo Noguchi,et al.  Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues , 2004, Nucleic Acids Res..

[31]  Shinzaburo Noguchi,et al.  Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Aldape,et al.  YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma , 2005, Clinical Cancer Research.

[33]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[34]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[35]  K. Mirnics,et al.  Platform influence on DNA microarray data in postmortem brain research , 2005, Neurobiology of Disease.

[36]  M. Wegner,et al.  Impact of transcription factor Sox8 on oligodendrocyte specification in the mouse embryonic spinal cord. , 2005, Developmental biology.

[37]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[38]  Rebecca A Betensky,et al.  YKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas , 2005, Clinical Cancer Research.

[39]  A. Brandes,et al.  Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Mariani,et al.  Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Ishikawa,et al.  Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. , 2006, Journal of neurosurgery.

[42]  Li Zhang,et al.  Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma , 2006, Clinical Cancer Research.

[43]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[44]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.